Financial results - ADYPHARM LUNCA SRL

Financial Summary - Adypharm Lunca Srl
Unique identification code: 30314021
Registration number: J2012000421017
Nace: 4773
Sales - Ron
509.138
Net Profit - Ron
35.044
Employees
3
Open Account
Company Adypharm Lunca Srl with Fiscal Code 30314021 recorded a turnover of 2024 of 509.138, with a net profit of 35.044 and having an average number of employees of 3. The company operates in the field of Comerţ cu amănuntul al produselor farmaceutice having the NACE code 4773.
Sales - Ron

Sales, Profit, Employees, Total Income, Financial Results - Adypharm Lunca Srl

2015 2016 2017 2018 2019 2020 2021 2022 2023 2024
Sales - EUR 150.409 192.959 241.887 282.214 277.097 333.814 327.162 422.954 496.443 509.138
Total Income - EUR 150.421 192.992 241.895 282.222 277.106 333.819 327.164 422.947 496.448 509.151
Total Expenses - EUR 133.596 167.056 216.014 260.382 246.017 298.772 292.219 403.954 468.154 467.286
Gross Profit/Loss - EUR 16.825 25.936 25.881 21.840 31.089 35.048 34.945 18.993 28.294 41.865
Net Profit/Loss - EUR 14.130 21.778 23.565 19.142 28.825 32.401 32.487 16.098 23.836 35.044
Employees 2 1 3 3 3 3 3 3 3 3
The table presents the most important indicators of the company from the Profit and Loss Account for the last 10 years of activity as found at the Ministry of Finance. The data provides the evolution of the company during this period regarding the increases and possibly decreases recorded. In the last year of activity, the sales increased by 3.1%, from 496.443 euro in the year 2023, to 509.138 euro in 2024. The Net Profit increased by 11.341 euro, from 23.836 euro in 2023, to 35.044 in the last year.
Sales - Ron
Net Profit - Ron
Employees

Check the financial reports for the company - Adypharm Lunca Srl

Rating financiar

Financial Rating -
ADYPHARM LUNCA SRL

See the company's note based on the submitted financial data, relative to the industry of which it is a part.

Financial Rating
Limite de plata

Payment Limits -
Adypharm Lunca Srl

See the company's payment capacity for situations in which you conclude contracts with payment terms.

Check Payment Limits
Probabilitate de insolventa

Prob. of insolvency -
Adypharm Lunca Srl

It determines the risk of insolvency based on the submitted accounting balance.

Insolvency Probability
Rapoarte financiare

Financial Reports -
Adypharm Lunca Srl

Check all the financial reports of the company and know the risks in collaboration with it.

Check Financial Reports
Financial Analysis Reports provide a clear and comprehensive view of a company's financial activity. In addition to presenting financial data, the reports analyze this data so that any user can understand whether the results are positive or less favorable. The Financial Rating provides an analysis based on the most important financial ratios, including liquidity, solvency, and profitability. Payment Limits represent the maximum amounts for which a company can offer goods or services on credit to its clients. The Probability of Insolvency presents the theoretical probability that a company may not be able to meet its financial obligations towards its creditors, i.e., suppliers and financial institutions.

Debts, Equity, Inventories, Receivables, Accounts, Assets - Adypharm Lunca Srl - CUI 30314021

2015 2016 2017 2018 2019 2020 2021 2022 2023 2024
Fixed Assets 61 60 285 280 275 270 264 2.541 2.247 1.956
Current Assets 72.405 74.908 104.018 119.277 97.767 155.833 152.710 173.124 188.107 198.893
Inventories 33.793 32.711 62.175 51.508 46.506 53.182 80.846 72.030 76.317 109.646
Receivables 11.045 7.922 29.775 48.403 34.235 80.042 55.940 82.083 85.384 41.514
Cash 27.568 34.276 12.067 19.366 17.026 22.609 15.924 19.011 26.406 47.733
Shareholders Funds 17.964 25.574 27.478 23.122 32.956 36.454 36.452 20.076 27.803 38.989
Social Capital 45 45 44 43 42 41 40 41 40 40
Debts 54.502 49.394 76.825 96.435 65.086 119.649 116.521 155.588 162.551 161.860
Income in Advance 0 0 0 0 0 0 0 0 0 0
Exchange rate - RON 4.9743 4.9465 4.9315 4.9468 4.8371 4.7454 4.6535 4.5681 4.4908 4.445
Main CAEN "4773 - 4773"
CAEN Financial Year 4773
The table presents the company's Balance Sheet structure for the last 10 years. Current Assets recorded a value of 198.893 euro in 2024 which includes Inventories of 109.646 euro, Receivables of 41.514 euro and cash availability of 47.733 euro.
The company's Equity was valued at 38.989 euro, while total Liabilities amounted to 161.860 euro. Equity increased by 11.341 euro, from 27.803 euro in 2023, to 38.989 in 2024.

Risk Reports Prices

Reviews - Adypharm Lunca Srl

Comments - Adypharm Lunca Srl

Similar services useful for checking companies and business development.

SellNet

Get the contact details for any company and get in touch with it.

Sectoral Studies

Knows the market and develops its own development strategies according to sectorial data.

Databases

Export in excel files the data of the companies selected according to the desired criteria.

Import - Export

Find importers and exporters according to the type of activity and the countries in which they carry it out.

Similar services represent services associated with companies that allow for a better analysis of clients and suppliers. Company Contacts help you get in touch with the desired companies. Sector Studies provide an overview of an industry, the most important competitors, and the geographical distribution of companies. Company Lists allow you to attract new clients, while Import-Export services give you access to companies engaged in such activities.